Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Luqa Pharma Gains China Rights to Women's Anti-Fungal

publication date: Mar 31, 2017
Shanghai's Luqa Pharma in-licensed China rights to Macmiror (Nifuratel), a product used to treat a wide range of infections in the genito-urinary tract. Luqa specifically mentioned vulvovaginal infections due to the pathogenic micro-organisms. Luqa acquired the product from Polichem, an Italian company that is a subsidiary of Spain's Almirall. Further details of the transaction were not disclosed. Luqa in-licenses products for China, focusing on dermatological products and women's health. Earlier this month, Luqa acquired Arista Pharma, also a China dermatological company. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital